Clinical Trial: Clinical Study on Systemic Treatment with RC48 Combined with Anti-PD-1 Monoclonal Antibody in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed BCG Intravesical Therapy (China)

China, Oct. 16 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Clinical Study on Systemic Treatment with RC48 Combined with Anti-PD-1 Monoclonal Antibody in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed BCG Intravesical Therapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134528

Registration Time: 2026/10/15

Type: Interventional study

Primary Sponsor: Department of Urology, The Second Hospital of Tianjin Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=234867

Published by HT Digital Content Services with permission from Health Daily Digest....